The FDA-approved DuoLith SD1 TT from CuraMedix is the next generation of extracorporeal shock wave therapy (ESWT), with focused CylindricalSource technology, as a nonsurgical treatment for pain associated with chronic proximal plantar fasciitis. The advantage of this new device is its time-tested, clinically robust, focused ESWT technology platform, powered by Storz Medical. The DuoLith SD1 TT is designed to address the increasing demand for patient convenience while minimizing down time and risk, maximizing clinical and economic outcomes, and improving practice efficiencies and cash flow.
View original post here:
CuraMedix DuoLith SD1 TT